Jane Street Group LLC Decreases Stock Position in 23andMe Holding Co. (NASDAQ:ME)

Jane Street Group LLC reduced its position in 23andMe Holding Co. (NASDAQ:ME) by 68.3% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 726,017 shares of the company’s stock after selling 1,561,678 shares during the period. Jane Street Group LLC’s holdings in 23andMe were worth $252,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in ME. GSA Capital Partners LLP purchased a new stake in 23andMe during the 3rd quarter valued at $805,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in 23andMe during the 2nd quarter valued at $203,000. AQR Capital Management LLC raised its stake in 23andMe by 145.8% during the 2nd quarter. AQR Capital Management LLC now owns 444,222 shares of the company’s stock valued at $174,000 after buying an additional 263,468 shares during the last quarter. FMR LLC raised its stake in 23andMe by 24.0% during the 3rd quarter. FMR LLC now owns 993,848 shares of the company’s stock valued at $345,000 after buying an additional 192,099 shares during the last quarter. Finally, Point72 DIFC Ltd purchased a new stake in 23andMe during the 2nd quarter valued at $43,000. 36.10% of the stock is currently owned by hedge funds and other institutional investors.

23andMe Price Performance

NASDAQ:ME opened at $3.84 on Friday. The firm has a market capitalization of $100.29 million, a price-to-earnings ratio of -0.15 and a beta of 1.14. 23andMe Holding Co. has a one year low of $2.65 and a one year high of $16.52. The business has a fifty day moving average price of $3.62 and a 200-day moving average price of $5.81.

23andMe (NASDAQ:ME) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($2.32) EPS for the quarter. The company had revenue of $44.07 million during the quarter, compared to analysts’ expectations of $50.30 million. 23andMe had a negative return on equity of 129.98% and a negative net margin of 318.39%.

About 23andMe

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.